beta
Trial Radar AI
Clinical Trial NCT05776147 (RADIANT) for Radiotherapy Side Effect is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One study matched filter criteria
Card View
Back to Search

Radiotherapy With Extreme Hypofractionation in Patients With Breast Cancer in Brazil: a Retrospective Cohort Study (RADIANT) 400

Recruiting
Clinical Trial NCT05776147 (RADIANT) is an observational study for Radiotherapy Side Effect that is recruiting. It started on 9 November 2023 with plans to enroll 400 participants. Led by Latin American Cooperative Oncology Group, it is expected to complete by 1 June 2025. The latest data from ClinicalTrials.gov was last updated on 7 March 2025.
Brief Summary
The radiotherapy scheme with extreme hypofractionation has gained space in clinical practice and, therefore, it is necessary to analyze the Brazilian national experience in selected patients with breast cancer, with the aim of evaluating the oncological outcomes and toxicities with the use of this treatment protocol.
Detailed Description
All patients diagnosed with breast cancer who meet the eligibility criteria at participating centers will be included. Data will be collected from medical records at selected centers. Data collection will start from the location activation date. Data from up to 500 patients are expected to be collected at centers across Brazil.

Patients recruited for this study will be identified at participating centers. Data on cl...

Show More
Official Title

Radiotherapy With Extreme Hypofractionation in Patients With Breast Cancer in Brazil: a Retrospective Cohort Study

Conditions
Radiotherapy Side Effect
Other Study IDs
  • RADIANT
  • LACOG 0122
NCT ID Number
NCT05776147
Start Date (Actual)
2023-11-09
Last Update Posted
2025-03-07
Completion Date (Estimated)
2025-06-01
Enrollment (Estimated)
400
Study Type
Observational
Status
Recruiting
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Locoregional recurrence
To evaluate the effectiveness of the extreme hypofractionation scheme, in 5 fractions of 5.2 Gy, in women with breast cancer
18 months
Participation Assistant
Eligibility Criteria

Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
Female
  • Women over 18 years old;
  • Diagnosis of breast cancer of any molecular subtype;
  • Undergoing extreme hypofractionated radiotherapy (5 x 5.2Gy) postoperatively;
  • Treated from December/2019 onward;
  • With clinical and treatment data available in medical records.

  • The protocol does not provide exclusion criteria.
Latin American Cooperative Oncology Group logoLatin American Cooperative Oncology Group
Study Central Contact
Contact: Laura Mendonça Diefenthäeler, +55 51 3384 5334, [email protected]
Contact: Laura Voelcker, +55 51 3384 5334, [email protected]
11 Study Locations in 1 Countries

Ceará

ICC - Instituto do Câncer do Ceará, Fortaleza, Ceará, 60.430-230, Brazil
Liêvin Matos Rebouças, Principal Investigator
Recruiting

Federal District

Hospital Sírio-Libanês DF, Brasília, Federal District, 70.200-730, Brazil
Gabriela de Siqueira, Principal Investigator
Not yet recruiting

Minas Gerais

Hospital Márcio Cunha da Fundação São Francisco Xavier (HMC-FSFX), Ipatinga, Minas Gerais, 35.160-158, Brazil
Harley Francisco de Oliveira, Principal Investigator
Not yet recruiting
Oncominas - Clínica de Oncologia no Sul de Minas, Pouso Alegre, Minas Gerais, 37.554-216, Brazil
Priscilla Furtado Souza Pasquinelli, Principal Investigator
Recruiting

Pernambuco

Real Hospital Português de Beneficência em Pernambuco, Recife, Pernambuco, 50.030-230, Brazil
Roberta Kramer Guedes Calixto da Silva, Principal Investigator
Not yet recruiting

São Paulo

Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto - USP, Ribeirão Preto, São Paulo, 14.015-010, Brazil
Gustavo Viani, Principal Investigator
Recruiting
Instituto COI - Clínicas Oncológicas Integradas (Instituto Américas RJ), Rio de Janeiro, 22.793-080, Brazil
Maria Carolina Perdigão, Principal Investigator
Recruiting
Hospital Sírio-Libanês SP, São Paulo, 01.308-050, Brazil
Samir Abdallah Hanna, Principal Investigator
Recruiting
HAOC - Hospital Alemão Oswaldo Cruz, São Paulo, 01.323-020, Brazil
Rodrigo Morais Hanriot, Principal Investigator
Recruiting
BP - A Beneficência Portuguesa de São Paulo, São Paulo, 01.323-030, Brazil
Robson Ferrigno, Principal Investigator
Recruiting
A.C. Camargo Cancer Center, São Paulo, 01.509-001, Brazil
Guilherme Rocha Melo Gondim, Principal Investigator
Recruiting